248 related articles for article (PubMed ID: 14508154)
1. Antimicrobial resistance among gram-positive organisms in the intensive care unit.
Clark NM; Hershberger E; Zervosc MJ; Lynch JP
Curr Opin Crit Care; 2003 Oct; 9(5):403-12. PubMed ID: 14508154
[TBL] [Abstract][Full Text] [Related]
2. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: emerging problems and new prospects for management.
Noskin GA
Ann Acad Med Singap; 2001 May; 30(3):320-31. PubMed ID: 11455748
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens].
Manfredi R
Recenti Prog Med; 2007 Mar; 98(3):143-54. PubMed ID: 17484159
[TBL] [Abstract][Full Text] [Related]
4. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
Lundstrom TS; Sobel JD
Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
[TBL] [Abstract][Full Text] [Related]
5. Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit.
Smith RL; Evans HL; Chong TW; McElearney ST; Hedrick TL; Swenson BR; Scheld WM; Pruett TL; Sawyer RG
Surg Infect (Larchmt); 2008 Aug; 9(4):423-31. PubMed ID: 18759679
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
Dowzicky MJ
Clin Ther; 2011 Dec; 33(12):1964-73. PubMed ID: 22078154
[TBL] [Abstract][Full Text] [Related]
7. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.
Jones RN; Low DE; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Feb; 33(2):101-12. PubMed ID: 10091033
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
10. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
11. Quinupristin-dalfopristin and linezolid: evidence and opinion.
Eliopoulos GM
Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
[TBL] [Abstract][Full Text] [Related]
12. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
14. Treatment of a vancomycin-resistant Enterococcus faecium ventricular drain infection with quinupristin/dalfopristin and review of the literature.
Tan TY; Pitman I; Penrose-Stevens A; Simpson BA; Flanagan PG
J Infect; 2000 Jul; 41(1):95-7. PubMed ID: 11041712
[TBL] [Abstract][Full Text] [Related]
15. [Update of antimicrobial resistance in Gram-positive microorganisms].
Cercenado E
Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699
[TBL] [Abstract][Full Text] [Related]
16. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
17. Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic.
Corti G; Cinelli R; Paradisi F
Int J Antimicrob Agents; 2000 Dec; 16(4):527-30. PubMed ID: 11118873
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.
Eliopoulos GM
Eur J Clin Microbiol Infect Dis; 2005 Dec; 24(12):826-31. PubMed ID: 16315008
[TBL] [Abstract][Full Text] [Related]
19. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
20. Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms.
Mendes RE; Deshpande LM; Jones RN
Drug Resist Updat; 2014 Apr; 17(1-2):1-12. PubMed ID: 24880801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
